A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD

Ken Ohta, Yoshinosuke Fukuchi, Lawrence Grouse, Ryuji Mizutani, Klaus F. Rabe, Stephen I. Rennard, Nan Shan Zhong

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

A large-scale prospective study was conducted in 3810 Japanese elderly (≥65 years old) patients with asthma or chronic obstructive pulmonary disease (COPD) who had been treated with sustained-release theophylline tablets (THEODUR®) at a dose of 400 mg/day for 1-6 months, in principle. Among 3798 protocol-complying patients (mean age: 73.8±0.10 years, 1997 with COPD), 261 theophylline-related adverse events were observed in 179 (4.71%) patients. The 5 most frequently observed adverse events were "nausea" (40 episodes, 1.05%), "loss of appetite" (22 episodes, 0.56%), "hyperuricemia" (16 episodes, 0.42%), "palpitation" (15 episodes, 0.39%), and "increased alkaline phosphatase" (11 episodes, 0.28%). No convulsions were reported. Six patients had serious adverse events. The incidence of theophylline-related adverse events was higher in patients with hepatic disease (odds ratio: 1:1.81) and in patients with arrhythmia (odds ratio: 1:1.88). Blood drug concentration measurements in 736 patients indicated that the drug levels were ≤15 μg/ml in 641 patients (87.1%), and no correlation was noted between dose and theophylline-related adverse events. These results suggest that sustained-release theophylline can be used safely in elderly patients with asthma or COPD.

Original languageEnglish (US)
Pages (from-to)1016-1024
Number of pages9
JournalRespiratory Medicine
Volume98
Issue number10
DOIs
StatePublished - Oct 1 2004

Fingerprint

Theophylline
Chronic Obstructive Pulmonary Disease
Asthma
Prospective Studies
Safety
Odds Ratio
Clinical Studies
Hyperuricemia
Appetite
Pharmaceutical Preparations
Nausea
Tablets
Alkaline Phosphatase
Cardiac Arrhythmias
Seizures
Liver
Incidence

Keywords

  • Adverse event
  • Bronchial asthma
  • Chronic obstructive pulmonary disease
  • Japanese elderly
  • Theophylline

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Ohta, K., Fukuchi, Y., Grouse, L., Mizutani, R., Rabe, K. F., Rennard, S. I., & Zhong, N. S. (2004). A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respiratory Medicine, 98(10), 1016-1024. https://doi.org/10.1016/j.rmed.2004.02.020

A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. / Ohta, Ken; Fukuchi, Yoshinosuke; Grouse, Lawrence; Mizutani, Ryuji; Rabe, Klaus F.; Rennard, Stephen I.; Zhong, Nan Shan.

In: Respiratory Medicine, Vol. 98, No. 10, 01.10.2004, p. 1016-1024.

Research output: Contribution to journalArticle

Ohta, K, Fukuchi, Y, Grouse, L, Mizutani, R, Rabe, KF, Rennard, SI & Zhong, NS 2004, 'A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD', Respiratory Medicine, vol. 98, no. 10, pp. 1016-1024. https://doi.org/10.1016/j.rmed.2004.02.020
Ohta K, Fukuchi Y, Grouse L, Mizutani R, Rabe KF, Rennard SI et al. A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respiratory Medicine. 2004 Oct 1;98(10):1016-1024. https://doi.org/10.1016/j.rmed.2004.02.020
Ohta, Ken ; Fukuchi, Yoshinosuke ; Grouse, Lawrence ; Mizutani, Ryuji ; Rabe, Klaus F. ; Rennard, Stephen I. ; Zhong, Nan Shan. / A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. In: Respiratory Medicine. 2004 ; Vol. 98, No. 10. pp. 1016-1024.
@article{5da0c85df45a40a7a1f813260e8392dc,
title = "A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD",
abstract = "A large-scale prospective study was conducted in 3810 Japanese elderly (≥65 years old) patients with asthma or chronic obstructive pulmonary disease (COPD) who had been treated with sustained-release theophylline tablets (THEODUR{\circledR}) at a dose of 400 mg/day for 1-6 months, in principle. Among 3798 protocol-complying patients (mean age: 73.8±0.10 years, 1997 with COPD), 261 theophylline-related adverse events were observed in 179 (4.71{\%}) patients. The 5 most frequently observed adverse events were {"}nausea{"} (40 episodes, 1.05{\%}), {"}loss of appetite{"} (22 episodes, 0.56{\%}), {"}hyperuricemia{"} (16 episodes, 0.42{\%}), {"}palpitation{"} (15 episodes, 0.39{\%}), and {"}increased alkaline phosphatase{"} (11 episodes, 0.28{\%}). No convulsions were reported. Six patients had serious adverse events. The incidence of theophylline-related adverse events was higher in patients with hepatic disease (odds ratio: 1:1.81) and in patients with arrhythmia (odds ratio: 1:1.88). Blood drug concentration measurements in 736 patients indicated that the drug levels were ≤15 μg/ml in 641 patients (87.1{\%}), and no correlation was noted between dose and theophylline-related adverse events. These results suggest that sustained-release theophylline can be used safely in elderly patients with asthma or COPD.",
keywords = "Adverse event, Bronchial asthma, Chronic obstructive pulmonary disease, Japanese elderly, Theophylline",
author = "Ken Ohta and Yoshinosuke Fukuchi and Lawrence Grouse and Ryuji Mizutani and Rabe, {Klaus F.} and Rennard, {Stephen I.} and Zhong, {Nan Shan}",
year = "2004",
month = "10",
day = "1",
doi = "10.1016/j.rmed.2004.02.020",
language = "English (US)",
volume = "98",
pages = "1016--1024",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD

AU - Ohta, Ken

AU - Fukuchi, Yoshinosuke

AU - Grouse, Lawrence

AU - Mizutani, Ryuji

AU - Rabe, Klaus F.

AU - Rennard, Stephen I.

AU - Zhong, Nan Shan

PY - 2004/10/1

Y1 - 2004/10/1

N2 - A large-scale prospective study was conducted in 3810 Japanese elderly (≥65 years old) patients with asthma or chronic obstructive pulmonary disease (COPD) who had been treated with sustained-release theophylline tablets (THEODUR®) at a dose of 400 mg/day for 1-6 months, in principle. Among 3798 protocol-complying patients (mean age: 73.8±0.10 years, 1997 with COPD), 261 theophylline-related adverse events were observed in 179 (4.71%) patients. The 5 most frequently observed adverse events were "nausea" (40 episodes, 1.05%), "loss of appetite" (22 episodes, 0.56%), "hyperuricemia" (16 episodes, 0.42%), "palpitation" (15 episodes, 0.39%), and "increased alkaline phosphatase" (11 episodes, 0.28%). No convulsions were reported. Six patients had serious adverse events. The incidence of theophylline-related adverse events was higher in patients with hepatic disease (odds ratio: 1:1.81) and in patients with arrhythmia (odds ratio: 1:1.88). Blood drug concentration measurements in 736 patients indicated that the drug levels were ≤15 μg/ml in 641 patients (87.1%), and no correlation was noted between dose and theophylline-related adverse events. These results suggest that sustained-release theophylline can be used safely in elderly patients with asthma or COPD.

AB - A large-scale prospective study was conducted in 3810 Japanese elderly (≥65 years old) patients with asthma or chronic obstructive pulmonary disease (COPD) who had been treated with sustained-release theophylline tablets (THEODUR®) at a dose of 400 mg/day for 1-6 months, in principle. Among 3798 protocol-complying patients (mean age: 73.8±0.10 years, 1997 with COPD), 261 theophylline-related adverse events were observed in 179 (4.71%) patients. The 5 most frequently observed adverse events were "nausea" (40 episodes, 1.05%), "loss of appetite" (22 episodes, 0.56%), "hyperuricemia" (16 episodes, 0.42%), "palpitation" (15 episodes, 0.39%), and "increased alkaline phosphatase" (11 episodes, 0.28%). No convulsions were reported. Six patients had serious adverse events. The incidence of theophylline-related adverse events was higher in patients with hepatic disease (odds ratio: 1:1.81) and in patients with arrhythmia (odds ratio: 1:1.88). Blood drug concentration measurements in 736 patients indicated that the drug levels were ≤15 μg/ml in 641 patients (87.1%), and no correlation was noted between dose and theophylline-related adverse events. These results suggest that sustained-release theophylline can be used safely in elderly patients with asthma or COPD.

KW - Adverse event

KW - Bronchial asthma

KW - Chronic obstructive pulmonary disease

KW - Japanese elderly

KW - Theophylline

UR - http://www.scopus.com/inward/record.url?scp=11144329060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144329060&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2004.02.020

DO - 10.1016/j.rmed.2004.02.020

M3 - Article

C2 - 15481279

AN - SCOPUS:11144329060

VL - 98

SP - 1016

EP - 1024

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 10

ER -